English
Locally Advanced Head and neck Cancer (LA-HNSCC) represents a significant clinical challenge. The standard of care (SOC) typically involves a combination of surgery, chemotherapy, and radiation therapy. However, there are significant limitations associated with these […]
For patients with unresected Locally Advanced Head & Neck Cancer (LA-SCCHN) who cannot undergo surgical resection, the current standard of care is high-dose cisplatin-based CRT which has shown to improve locoregional control, PFS and OS compared […]
The medical community eagerly anticipates Curis’ next steps after their revolutionary drug, Emavusertib (CA-4948), experienced a significant milestone: the lifting of the FDA’s clinical hold. Here’s an in-depth look at what this development means for […]
As Actinium forges ahead with its transformative therapies, including Iomab-B and Actimab-A, its strategic approach extends beyond clinical trials and regulatory milestones. Actinium’s presentation of six abstracts at the Society for Nuclear Medicine and Molecular […]
